Archive for the 'Serum Marker/Blood Test' Category
September 22nd, 2007. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?
Taken together, we suggest that PAX2 is a novel Müllerian-specific epithelial marker when used in proper clinical settings. Identification of PAX2 in the majority of papillary serous carcinomas of the ovary but not in the ovarian surface epithelium or epithelium-derived inclusion cysts suggests that this malignant epithelial tumor may be directly derived from the primary or secondary Müllerian epithelium in or surrounding the ovary, rather than from the surface epithelium or its derivatives.
September 6th, 2007. Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
Conclusions: Our data confirm that serum SMRP is a promising marker for the diagnosis, prognosis, and clinical monitoring of MM. We found that serum SMRP dosage may prove helpful in LC diagnosis as well. These data may also have positive repercussions on secondary preventive medical strategies for workers previously exposed to asbestos.
September 4th, 2007. Assessment of tumor response in malignant pleural mesothelioma
The use of FDG-PET for prediction of response and, more importantly, of survival outcomes of MPM patients is promising and warrants validation in large prospective series. New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment.
Posted in Chemotherapy, CT or CAT scan, Diagnosis & Differentiation, Full Archive, PET Scan, Pleural, RECIST, Serum Marker/Blood Test, Staging, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 2nd, 2007. h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary
3%). The relationship between the values of sensitivity and specificity of each marker using receiver operating characteristic analysis permitted the identification of h-CD, calretinin, ER, and Ber-EP4 as the markers with the best performance in differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
July 31st, 2007. DNA methylation profile of 28 potential marker loci in malignant mesothelioma
0003). Examination of associations between methylation levels of the 28 loci and clinical parameters suggest associations of the methylation status of metallothionein genes with gender, histology, asbestos exposure, and lymph node involvement, and the methylation status of leucine zipper tumor suppressor 1 (LZTS1) and SLC6A20 with survival.
July 25th, 2007. Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma
Conclusion: Combining mesothelin and CA125 data does not improve the sensitivity of mesothelioma diagnosis over mesothelin alone. The use of both markers potentially increases the number of patients who can be monitored. Key Words: CA125, malignant mesothelioma, mesothelin, SMRP, tumor markers
May 17th, 2007. Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
Conclusions: Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. Insufficient specificity limits osteopontin utility as diagnostic marker. Both molecules have a potential value as prognostic markers.
May 9th, 2007. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
Conclusions: SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.
April 12th, 2007. Establishment of the enzyme-linked immunosorbent assay system to detect the amino terminal secretory form of rat Erc/Mesothelin.
There are several rat model systems of mesothelioma that may be promising tools in the development of an antimesothelioma treatment. We hope our ELISA to detect the soluble form of rat Erc/Mesothelin is useful in the rat model system to exploit the antimesothelioma therapy to be used in human cases.
March 29th, 2007. Can serum inflammatory parameters estimate outcome of pleurodesis in mesothelioma?
Conclusion: Serum levels of inflammatory parameters (C-reactive protein and erythrocyte sedimentation rate) may be used to predict the success of pleurodesis in patients with malign mesothelioma who underwent thoracoscopic talc poudrage.
March 21st, 2007. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations
Osteopontin expression is not restricted to malignant mesothelial proliferations, and immunohistochemical analysis for osteopontin is not helpful in determining reactive vs malignant mesothelial proliferations. The reported usefulness of osteopontin as a serum tumor marker for mesothelioma may be due to differences in the amount or character of secreted protein in malignant mesothelioma compared with reactive mesothelial proliferations.
March 9th, 2007. Blood tests for asbestos-related mesothelioma
Recently, serum markers for the diagnosis of mesothelioma have been reported as candidates. In this paper, we mini-reviewed the potential utility of ELISA systems as serum diagnostic markers for asbestos-related mesothelioma.
February 23rd, 2007. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples
No viral DNA was found in the sera. No significant association between SV40 antibody response in prediagnostic sera and risk of mesothelioma was seen.
February 10th, 2007. MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma
Conclusions: The MESOMARK assay is analytically robust and may be useful for the detection and management of mesothelioma.
November 23rd, 2006. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement
Conversely, to differentiate between MM and PSCC, p63 and WT-1 are the best available markers. We recommend a panel of CK5/6, p63, D2-40, and WT-1 to differentiate MM from pulmonary carcinomas in effusion cytology specimens.
November 15th, 2006. Use of mesothelin as a marker for mesothelial cells in cytologic specimens
As a marker for mesothelial cells, the sensitivity and specificity of mesothelin were 73% and 55%, respectively, and the sensitivity and specificity of calretinin were 95% and 86%, respectively. Therefore, mesothelin is not a sensitive or a specific marker for mesothelial cells in cytologic specimens when compared with calretinin.
October 17th, 2006. Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers
It has also been found that N-ERC/mesothelin is very stable and plentiful in the blood. In the present paper the potential utility of molecular diagnostic markers is reviewed, including ELISA systems for asbestos-related mesothelioma.
September 13th, 2006. Cytogenetic and molecular genetic changes in malignant mesothelioma
Ongoing studies are already applying high-throughput genomic profiling methods in MM. Genetic alterations observed in MM may be useful in differential diagnosis between lung cancer and MM, as diagnostic markers or therapeutic targets, and as indicators of premalignancy for primary prevention and health surveillance.
September 6th, 2006. Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma
This protein may regulate proliferation linked with differentiation toward epithelioid morphology in mesothelial cells. Expression of the protein may be a prognostic indicator for patents with malignant mesothelioma.
August 22nd, 2006. Diagnostic value of markers M2A, OCT3/4, AP-2gamma, PLAP and c-KIT in the detection of extragonadal seminomas
M2A and AP-2gamma are the most sensitive markers for seminoma metastases or primary extragonadal seminomas. Combination of these markers provides highly specific and clear results for detection of a seminomatous GCT.
|
|  |
